Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET III: Continuous vs Intermittent Flucloxacillin/Cefazolin in CSAI
NCT05655091Phase 2Recruiting
- Sponsor
- University Hospital Basel
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of flucloxacillin and cefazolin in Staphylococcus aureus infection (2 arms), sponsored by University Hospital Basel. Primary endpoint: Proportion of patients that attain the target concentration (100% fT 2 to 12 mg/L) in blood at Day 3. Started Oct 2023; status: recruiting.
02
Drugs
flucloxacillincefazolin
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT05655091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05655091.